Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid ...
A common genetic pathway may account for increased risk for atherosclerotic disease in patients with chronic widespread musculoskeletal pain. Chronic widespread pain (CWP) and atherosclerotic disease ...
The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.